Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects
Status:
Withdrawn
Trial end date:
2019-05-03
Target enrollment:
Participant gender:
Summary
This study is a Phase 3, double blind, placebo controlled, randomized, stratified, parallel
group, multi-center clinical trial designed to compare the efficacy and safety of bococizumab
150 mg SC Q2wks to placebo for LDL-C lowering in subjects with primary hyperlipidemia or
mixed dyslipidemia at high or very high risk for CV events. The study will enroll a total of
approximately 750 subjects from 4 - 5 Asian countries/areas (including China mainland); of
which approximately 600 subjects will be from sites in China. Subjects will be randomized
into a bococizumab treatment arm and a placebo arm in a 1:1 ratio.